CQ Medical to Showcase Innovative Radiotherapy Positioning Solutions at ESTRO 2025, Booth #370
Empowering Medical Excellence Through Intelligence and Empathy
Coralville, Iowa, (April 15, 2025) – CQ Medical, the global leader in patient radiotherapy positioning and healthcare innovation, will highlight its latest advancements at the ESTRO 2025 Congress in Vienna, Austria, from May 2–6, at booth #370.
Built on the philosophy that intelligence (IQ) + empathy (EQ) = Care Quotient (CQ), CQ Medical applies both IQ and EQ to every product and solution it develops. Over the past year, the company has focused on transforming ideas into innovations that advance precision, enhance technology, and empower medical excellence to achieve better patient outcomes.
Featured Solutions at ESTRO 2025
SBRT Respiratory Restriction Options
CQ Medical brings together three best-in-class products—Body Pro-Lok™ ONEBridge™, ONE Respiratory Belt, and the ZiFix Traverse™ Motion Control System—to create a cohesive, comprehensive solution for SBRT positioning. These systems now integrate seamlessly with CQ’s leading couchtops and platforms, simplifying setup and improving reproducibility.
Patient Transfer – Symphony® Imaging, Treatment & Transfer Solutions
The Symphony system combines the AirShuttle™ patient platform and AirDrive™ system to enable smooth transfers across multiple imaging and treatment environments—including CT, MRI (up to 3 Tesla), ultrasound, brachytherapy, and photon/proton therapy. This innovation enhances workflow efficiency, patient comfort, and precision.
Brachytherapy Innovations
The combination of the Lithotomy AirShuttle and Alpine Stirrups offers smarter solutions for brachytherapy procedures by eliminating the need for patient repositioning between imaging and treatment. The MR-conditional stirrups are designed for easy setup and secure positioning while providing enhanced anatomical access. Featuring an integrated rail attachment clamp to prevent lost components, they are also 20% lighter (as of 07/2024) than other stirrups on the market, promoting greater ease of use.
Proton Therapy – Pronumbra™ Head & Neck Solution
CQ Medical continues to set the standard in proton therapy positioning with with a range of market-leading couchtops, head and neck immobilization, and additional disease site specific positioning solutions, including a complete pediatric offering. The new Pronumbra Head & Neck solution is designed with physicists' concerns in mind and is optimized to streamline therapists' workflows.
Largest Selection of Fiducial Markers
CQ Medical offers the most extensive range of specially designed fiducial markers to support accurate tumor localization—even in areas where internal anatomy shifts relative to external landmarks. The lineup includes BioXmark®, a novel liquid fiducial marker that allows clinicians to implant multiple markers of varying sizes in one uninterrupted procedure. Its soft, sticky form adapts to surrounding soft tissue, providing exceptional positional stability and visibility across many disease sites.
About CQ Medical
CQ Medical is the global leader in developing high-quality, innovative, patient-centric radiotherapy and cancer therapy solutions. With primary locations in Iowa and Pennsylvania and employees worldwide, the company has more than 80 years of combined experience bringing advanced hardware and consumables for patient immobilization and positioning, fiducial markers, couchtops, and patient care products to the market. Learn more at CQmedical.com.
For media inquiries, please contact:
Kelly Hazelett, Sr. Marketing Content Manager, marketing@CQmedical.com
COPYRIGHT © 2025 CQ Medical. All rights reserved. CQ Medical is a registered trademark of Medtec LLC. Alpine, Body Pro-Lok ONE, and ONEBridge are trademarks of Medtec LLC. Symphony is a registered trademark of Qfix Systems LLC. AirDrive, AirShuttle, and Pronumbra are trademarks of Qfix Systems LLC. BioXmark is a registered trademark of Nanovi A/S. This press release contains information about products that may or may not be available in particular countries. These products may not be licensed in accordance with Canadian law. Each country has specific laws and regulations governing the commercialization of medical devices and the communication of information regarding medical devices in printed and digital media. Products appearing in this press release or on our website may or may not have received approval, clearance, or marketing authorization by a governmental regulatory body in any particular country or may have received approval, clearance, or marketing authorization for different indications and restrictions in different countries or may be for investigational use only.
CQ2025D31 Rev. 0
###